Tesaro stock soars on an­oth­er re­port the PARP play­er is ex­plor­ing a sale

At some point some­body might buy can­cer drug­mak­er Tesaro $TSRO, but un­til then it looks like in­vestors will be sub­ject­ed to a seem­ing­ly end­less ar­ray of re­ports sug­gest­ing the PARP play­er is putting it­self up on the auc­tion block.

Fresh on the heels of un­der­whelm­ing drug da­ta pre­sent­ed at a con­fer­ence ear­li­er this month that sent the com­pa­ny’s shares in­to a tail­spin, Tesaro’s ane­mic stock price this year may make it an at­trac­tive tar­get for on­col­o­gy-fo­cused play­ers, sug­gest­ed Bloomberg on Fri­day in a re­port that said the com­pa­ny was ex­plor­ing a sale, cit­ing peo­ple fa­mil­iar with the mat­ter.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER